Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Non-Current Debt for 5 consecutive years, with $396.1 million as the latest value for Q2 2022.

  • On a quarterly basis, Non-Current Debt rose 5.61% to $396.1 million in Q2 2022 year-over-year; TTM through Jun 2022 was $396.1 million, a 5.61% increase, with the full-year FY2020 number at $372.9 million, up 70.03% from a year prior.
  • Non-Current Debt was $396.1 million for Q2 2022 at Theravance Biopharma, up from $384.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $396.1 million in Q2 2022 to a low of $217.7 million in Q2 2019.
  • A 5-year average of $323.0 million and a median of $374.5 million in 2020 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: dropped 4.46% in 2019, then soared 73.18% in 2020.
  • Theravance Biopharma's Non-Current Debt stood at $229.5 million in 2018, then decreased by 4.46% to $219.3 million in 2019, then surged by 70.03% to $372.9 million in 2020, then rose by 0.72% to $375.6 million in 2021, then increased by 5.47% to $396.1 million in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Non-Current Debt are $396.1 million (Q2 2022), $384.2 million (Q1 2022), and $375.6 million (Q3 2021).